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OBJECTIVES We investigated whether N-acetylcysteine (NAC), a reduced thiol that modulates redox state
and forms adducts of nitric oxide (NO), improves endothelium-dependent vasomotion.
BACKGROUND Coronary atherosclerosis is associated with endothelial dysfunction and reduced NO activity.
METHODS In 16 patients undergoing cardiac catheterization, seven with and nine without atheroscle-
rosis, we assessed endothelium-dependent vasodilation with acetylcholine (ACH) and
endothelium-independent vasodilation with nitroglycerin (NTG) and sodium nitroprusside
(SNP) before and after intracoronary NAC. In 14 patients femoral vascular responses to
ACH, NTG and SNP were measured before and after NAC.
RESULTS Intraarterial NAC did not change resting coronary or peripheral vascular tone.
N-acetylcysteine potentiated ACH-mediated coronary vasodilation; coronary blood flow was
36 6 11% higher (p , 0.02), and epicardial diameter changed from 21.2 6 2% constriction
to 4.7 6 2% dilation after NAC (p 5 0.03). Acetylcholine-mediated femoral vasodilation was
similarly potentiated by NAC (p 5 0.001). Augmentation of the ACH response was similar
in patients with or without atherosclerosis. N-acetylcysteine did not affect NTG-mediated
vasodilation in either the femoral or coronary circulations and did not alter SNP responses in
the femoral circulation. In contrast, coronary vasodilation with SNP was significantly greater
after NAC (p , 0.05).
CONCLUSIONS Thiol supplementation with NAC improves human coronary and peripheral endothelium-
dependent vasodilation. Nitroglycerin responses are not enhanced, but SNP-mediated
responses are potentiated only in the coronary circulation. These NO-enhancing effects of
thiols reflect the importance of the redox state in the control of vascular function and may be
of therapeutic benefit in treating acute and chronic manifestations of atherosclerosis. (J Am
Coll Cardiol 2001;37:117–23) © 2001 by the American College of Cardiology
The endothelium is central to the regulation of vascular
smooth muscle tone, hemostasis, inflammation and lipopro-
tein oxidation by generating nitric oxide (NO) (1). Endo-
thelial dysfunction, associated with reduced NO bioavail-
ability, is an early event in the pathogenesis of
atherosclerosis (2). Atherosclerosis and its risk factors in-
cluding hypercholesterolemia, hypertension and diabetes are
associated with the generation of oxygen free radicals that
degrade NO (3–5). Diminished NO activity, by upregulat-
ing nuclear factor kappa beta and expression of inflamma-
tory cytokines and adhesion molecules (6), predisposes
atherosclerotic lesions to vasoconstriction, increased platelet
adhesion and aggregation and thrombus formation (2).
Improving NO bioavailability may, therefore, reverse endo-
thelial dysfunction, improve ischemia, reduce the risk of
thrombotic complications and modify the progression of
atherosclerosis.
Reduced thiols are molecules with a sulfhydryl group that
have many biological functions, including scavenging oxy-
gen free radicals, acting as cofactors for enzymatic reactions
and modifying the half-life of NO by forming NO adducts
(7). N-acetylcysteine (NAC), a thiol, is a pharmacological
precursor of L-cysteine. When administered in its reduced
form, NAC rapidly increases systemic levels of cysteine (8).
The properties of NO adducts (S-nitrosothiols) vary accord-
ing to the thiol group. For example, S-nitrosocysteine has a
short half-life but vasodilates and activates guanylate cyclase
more potently than NO, whereas NO adducts of proteins
may act as important stable reservoirs of NO (9–12).
Hence, NO adducts appear to be the principal intermediates
in the action of NO, and thiols may potentiate the activity
of NO by either forming more biologically active adducts,
by scavenging free radicals or by preventing NO oxidation
and degradation.
Experimental studies have demonstrated that exogenous
reduced thiols potentiate the effects of endogenous and
exogenous NO (9,13,14). To determine whether exogenous
thiols have similar effects in humans and, in particular,
patients with atherosclerosis or its risk factors, we studied
the effects of NAC in the human coronary and peripheral
circulations. The effect of NAC on endogenous NO was
studied by using the endothelium-dependent agonist ace-
tylcholine (ACH), and the effect on exogenous NO donors
was studied by using nitroglycerin (NTG) and sodium
nitroprusside (SNP).
METHODS
Coronary vascular study. PATIENTS. We studied 16 pa-
tients, 7 with coronary atherosclerosis and 9 with angio-
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graphically normal coronary arteries (Table 1), who were
undergoing diagnostic cardiac catheterization for investiga-
tion of chest pain or abnormal noninvasive tests. There were
nine (56%) men, and the mean age was 50 6 11 years
(Table 1). Patients with recent myocardial infarction, val-
vular heart disease or severe heart failure were excluded.
PROTOCOL. All cardiac medications were withdrawn at
least 48 h before the study, and aspirin or other cyclooxy-
genese inhibitors were discontinued seven days before. The
National Heart, Lung and Blood Institute’s Institutional
Review Board approved the study, and informed consent
was obtained from all patients.
After diagnostic coronary angiography was performed, a
6F guide catheter was introduced into the proximal segment
of a coronary artery, and blood flow velocity was measured
using a 0.018 inch wire equipped with a Doppler crystal at
its tip (Cardiometrics, Endosonics Corp., Rancho Cordova,
California). The Doppler wire was advanced into either the
left main or the proximal segment of a major epicardial
artery free of significant stenosis (,30%). The wire tip was
carefully positioned in a segment of the vessel that was
straight and free of any major branches 1 cm from the tip
that produced an adequate flow velocity signal and could be
imaged without overlap from other vessels for quantitative
measurements of the coronary artery diameter (15,16).
EFFECT OF NAC ON CORONARY VASCULAR RESPONSES TO
ACH, NTG AND SNP. After a 5-min infusion of dextrose 5%
at 1 ml/min, measurement of coronary blood flow velocity
and coronary angiography were performed and repeated
after each intervention. Endothelium-dependent vasodila-
tion was estimated by performing a dose-response curve
with 2-min incremental infusions of intracoronary ACH
starting at 3 mg/min in patients with atherosclerosis and at
30 mg/min in those with normal coronary arteries. This
regimen avoided excessive constriction that may occur at
higher doses of ACH in atherosclerotic coronary arteries.
The dose of ACH was not increased further once the
infusion either reduced blood flow velocity or severely
(.50%) narrowed the epicardial coronary tree. All patients
received the 30 mg/min concentration of ACH.
Endothelium-independent function was estimated with
two NO donors; NTG was infused for 2 min each at 7.5 and
15 mg/min. After a 10-min period, SNP was infused at 20
and 40 mg/min for 3 min each. After this, coronary flow
reserve was measured with intracoronary adenosine admin-
istered at 2.2 mg/min for 2 min.
After a 15-min rest period and return of flow velocity to
baseline values, an intracoronary infusion of NAC was
started at 48 mg/min for 10 min. While continuing the
NAC infusion, ACH was readministered at 30 mg/min,
NTG at 7.5 and 15 mg/min, SNP at 20 mg/min and
adenosine at 2.2 mg/min for 2 min.
MEASUREMENT OF CORONARY BLOOD FLOW AND DIAME-
TER. Coronary blood flow was derived from the coronary
blood flow velocity and diameter measurements using the
formula (p 3 average peak velocity 3 0.125 3 diameter2).
Coronary vascular resistance was calculated as mean arterial
pressure 4 coronary blood flow. For calculating flow,
coronary artery diameter was measured in a 0.5-cm segment
of vessel beginning 0.25 cm beyond the tip of the Flowire.
Coronary angiograms were recorded using a cineangio-
graphic system (Toshiba, Inc.), and quantitative angiogra-
phy was performed with the ARTEK software (Quantim
2001, Statview, ImageComm Systems, Inc.). In addition to
the measurement of the diameter at the level of the Doppler
flow wire, 0.5-cm segments of mid- and distal regions of the
epicardial coronary arteries were also measured by quanti-
tative coronary angiography (15,16).
Because coronary epicardial vasodilation caused by NTG
and NTP was not completely reversed by waiting 15 min
after these drugs were given, we performed a separate
analysis in segments of coronary arteries that returned to
within 6 10% of the baseline measurement. Coronary blood
flow, however, returned to baseline 15 min after NTG and
NTP.
REPRODUCIBILITY. The reproducibility of the coronary vas-
cular responses to ACH was evaluated using two 30 mg/min
infusions of ACH in five patients. Coronary blood flow
(183 6 45 and 161 6 35 mL/min, p 5 0.5) and diameter
(1.74 6 0.2 and 1.73 6 0.2 mm, p 5 0.5, n 5 15) were
similar during the two infusions. The diameters were
reproducible in the segments that dilated (2.12 6 0.3 and
2.08 6 0.3 mm, n 5 7, p 5 0.4) and those that constricted
(1.42 6 0.1 and 1.43 6 0.1 mm, n 5 8, p 5 0.5) with the
first infusion of ACH. All segments that constricted with
the first infusion also constricted during the second infusion.
Femoral vascular study. PATIENTS. We studied 14 pa-
tients (12 of whom also underwent the coronary vascular
Abbreviations and Acronyms
ACH 5 acetylcholine
CV 5 coefficient of variation
NAC 5 N-acetylcysteine
NO 5 nitric oxide
NTG 5 nitroglycerin
SNP 5 sodium nitroprusside
Table 1. Patient Characteristics
Variables
Study
Coronary Femoral
Number 16 14
Men 10 9
Age, y 50.5 6 3 48 6 3
Cholesterol, mg/dl 201 6 11 219 6 12.4
HDL, mg/dl 38 6 2 42 6 3
Hypertension, n 3 3
Diabetes, n 2 3
Current smoking, n 5 5
Atherosclerosis, n 7 7
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study .3 h before), seven with and seven without athero-
sclerosis of the coronary or the iliofemoral circulation. Their
mean age was 48 6 2.7 years; nine were men.
PROTOCOL. A 6F multipurpose A2 (Cordis, Inc.) catheter
was introduced retrogradely 1 cm beyond the end of a 7F
femoral artery sheath. A 0.018 inch Doppler Flowire was
introduced through the catheter and positioned 1 cm
beyond the catheter tip to obtain an adequate flow velocity
signal. All drugs were infused through the catheter 1 to
2 cm below the tip of the Doppler wire (17,18). A femoral
angiogram was performed to assist with positioning of the
wire and to visualize obstructive atherosclerotic plaques in
the iliofemoral circulation, which may compromise blood
flow measurements. Since diameter measurements were not
made at the level of the Doppler wire with each interven-
tion, we calculated the femoral vascular resistance index as
the mean arterial pressure 4 femoral blood flow velocity.
EFFECT OF NAC ON FEMORAL VASCULAR RESPONSES TO
ACH, NTG AND SNP. After measurement of baseline flow
velocity and mean arterial pressure, endothelium-dependent
vasodilation was estimated by performing a dose-response
curve with incremental infusions of ACH at 150 and 300
mg/min for 2 min each. Endothelium-independent function
was estimated with two NO donors; NTG at 25 mg/min for
3 min and SNP at 20 mg/min for 2 min.
After a 15-min recovery period, NAC was infused in-
traarterially at 48 mg/min for 10 min to achieve an esti-
mated intraarterial concentration of 2 mol/liter. While
continuing the infusion of NAC at 48 mg/min, ACH was
coinfused at 150 mg/min and at 300 mg/min for 2 min each.
After a 10-min recovery period, the NAC infusion was
continued and coinfused with NTG at 25 mg/min for 3 min
and SNP at 20 mg/min for 2 min. Blood flow velocity and
mean arterial pressure were measured after each intervention.
REPRODUCIBILITY. Reproducibility of the microvascular
dilator response to repeated infusions of ACH and SNP was
tested in six patients during infusion of D5W. The femoral
vascular resistance indexes during the first and second
infusions were as follows: ACH (150 mg/min), 3.5 6 0.6
and 4.0 6 0.6, p 5 0.2 (coefficient of variation [CV]
17.2%); ACH (300 mg/min), 3.1 6 0.5 and 3.7 6 0.6, p 5
0.2 (CV 8.2%); SNP, 1.8 6 0.1 and 1.8 6 0.2, p 5 0.7 (CV
8.7%). These findings are consistent with our previously
described reproducibility of vascular responses in the fem-
oral circulation (17,18).
Statistical analysis. Data are expressed as mean 6 SEM.
Differences between means were compared by paired or
unpaired Student t-test, as appropriate. The effect of NAC
on the effect of NTG in the coronary circulation and of
ACH in the femoral circulation were compared by two-way
analysis of variance for repeated measures with drug and
dose as main effects and drug X dose interaction (Sigmastat,
Version 1.0). If the F value was significant, a Bonferroni
multiple comparison test was performed. All p values were
two-tailed, and a value ,0.05 was considered to be of
statistical significance.
RESULTS
Coronary microcirculation. EFFECT OF NAC ON THE RE-
SPONSES TO ACH. After 10 min of NAC infusion, heart
rate (75 6 3.1 to 75 6 3.0 beats/min, p 5 0.9) and mean
arterial pressure (109 6 4.1 to 109 6 3.8 mm Hg, p 5 0.5)
remained unchanged. There was also no change in coronary
blood flow (41.1 6 4.8 to 39.3 6 5.1 ml/min, p 5 0.3) or
coronary vascular resistance (3.2 6 0.4 to 3.9 6 0.8 mm
Hg.ml21.min, p 5 0.2).
N-acetylcysteine augmented ACH-mediated microvas-
cular dilation, indicating significant potentiation of
endothelium-dependent vasomotion. Compared with base-
line responses with 30 mg/min ACH, coronary vascular
resistance was 21 6 6% lower, p , 0.01 (Fig. 1). This
potentiating effect of NAC was observed in patients with
normal coronary arteries (vascular resistance fell from
241 6 7% to 254 6 8%, p 5 0.01), and those with
atherosclerosis (vascular resistance changed from 222 6
12% to 241 6 10%, p 5 0.07).
EFFECT OF NAC ON THE RESPONSE TO SNP. Sodium nitro-
prusside produced graded microvascular dilation that was
potentiated by NAC. Thus, compared with baseline, NAC
produced a further 68% increase in coronary blood flow
(p , 0.01) at the 20 mg/min dose (Fig. 2).
Figure 1. Change in coronary vascular resistance, coronary blood flow and
epicardial diameter in response to acetylcholine before (control) and after
N-acetylcysteine (NAC). P values compare control versus NAC.
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EFFECT OF NAC ON THE RESPONSE TO NTG. Nitroglycerin
did not alter resting coronary blood flow or vascular resis-
tance, and NAC did not affect responses to NTG (Fig. 3).
EFFECT OF NAC ON THE RESPONSE TO ADENOSINE. Intra-
coronary adenosine produced microvascular vasodilation
that was also unaffected by NAC. The baseline increase in
coronary blood flow of 366 6 33% remained unchanged
after NAC (387 6 57%, p 5 NS, respectively; Fig. 4).
Coronary epicardial response to NAC. In the group as a
whole, there was a mild residual vasodilation in the 46
epicardial coronary segments measured 15 min after the
administration of NTG, NTP and adenosine (from 1.95 6
0.1 to 2.15 6 0.1 nm, p , 0.01). To overcome the effect of
this baseline shift, we examined the effects of ACH, NTP
and NTG on 31 epicardial segments that returned to their
baseline diameter (1.92 6 0.1 before and 1.94 6 0.1 after an
NAC).
Acetylcholine (30 mg/min) produced a 1.4 6 2% con-
striction in mean epicardial vessel diameter at baseline.
After NAC, this was improved to 4.7 6 2% dilation, p 5
0.033 (Fig. 1). Similarly, epicardial dilation in response to
SNP (20 mg/min) was improved by NAC: 17.5 6 3%
before to 24.7 6 3% after NAC, p 5 0.03 (Fig. 2). In
contrast, NTG-mediated epicardial dilation at the 7.5 and
15 mg/min concentrations remained unchanged after NAC
(19.4 6 3% to 20.1 6 3%, p 5 NS) before versus after
NAC, respectively, at the low dose of NTG (Fig. 3).
Effect of NAC on femoral microcirculation.
N-acetylcysteine infusion did not alter resting arterial pres-
sure or femoral microvascular tone; femoral vascular resis-
tance index was 5.8 6 0.6 before and 5.1 6 0.6 mm
Hg.m21.s, p 5 0.8 after NAC. Acetylcholine produced
progressive vasodilation of the femoral microcirculation that
was significantly potentiated by NAC, p 5 0.001 by analysis
of variance (Fig. 5). This effect was greater at the lower dose
Figure 2. Change in coronary vascular resistance, coronary blood flow and
epicardial diameter in response to sodium nitroprusside before (control)
and after N-acetylcysteine (NAC).
Figure 3. Change in coronary vascular resistance, coronary blood flow and
epicardial diameter in response to nitroglycerin before (control) and after
N-acetylcysteine (NAC).
Figure 4. Change in coronary vascular resistance and coronary blood flow
in response to intracoronary adenosine before (control) and after
N-acetylcysteine (NAC).
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of ACH. Improvement was observed in patients with
normal and depressed baseline responses to ACH.
Unlike the coronary circulation, SNP-mediated femoral
vasodilation was not enhanced by NAC (Fig. 5). Similar to
the coronary circulation, no increase in NTG-induced
vasodilation was observed in the femoral microcirculation
after NAC (Fig. 5).
DISCUSSION
The three major findings of this study were: 1) NAC, a
reduced thiol, improves endothelium-dependent vasomo-
tion in the coronary and peripheral circulations of patients
with and without atherosclerosis, 2) NAC potentiates SNP-
mediated coronary, but not femoral, vasodilation and 3)
NAC did not potentiate NTG-mediated coronary or fem-
oral vasodilation.
Effect of NAC on endothelium-dependent vasodilation.
Another reduced thiol, glutathione, also improves endothe-
lial dysfunction in atherosclerosis by enhancing stimulated
NO activity (19,20). In this study, we show that NAC has
no effect on basal vasomotor tone but improves
endothelium-dependent responses. This effect was observed
in patients with and without endothelial dysfunction or
atherosclerosis.
Potential mechanisms underlying the improvement in
endothelial function with NAC. N-acetylcysteine may
enhance the bioavailability of NO by spontaneously forming
S-nitroso-N-acetylcysteine and a stable, biologically active
transnitrosation byproduct, S-nitrosocysteine (21,22).
Though NO has a very short half-life, in the order of 0.1 to
1 s, evidence suggests that it circulates in the plasma
primarily as S-nitrosoalbumin after reacting with the sulf-
hydyl group of cysteine 34 and in red blood cells as
nitrosyl-hemoglobin and S-nitrosohemoglobin (21–23).
S-nitrosoalbumin is biologically active but has minimal
intracellular access and probably serves as a circulating
reservoir of NO (23). Low molecular weight thiols, such as
cysteine, form less diffusion-limited NO adducts that may
transport NO to target sites within vascular smooth muscle
cells and platelets (21).
The second potential mechanism for action of NAC may
relate to its antioxidant properties (11,12,14). Increased
generation of oxygen free radicals, largely responsible for
inactivating NO (3–5,24), may be scavenged from plasma or
endothelial cells by NAC, thereby increasing NO bioavail-
ability (3–5,24–26). Support for this mechanism is provided
by the observation that NAC does not potentiate
endothelium-dependent vasodilation in normal volunteers
in whom oxidative stress is low (27).
The effect of NAC on exogenous NO donors. Nitroglyc-
erin requires enzymatic metabolism in the cell membrane of
vascular smooth muscle cells to liberate NO (28). Thus,
exogenously administered thiols would need to elevate
vascular interstitial levels to potentiate NTG responses. In
our study, NTG-mediated microvascular vasodilation was
not potentiated by NAC, contrary to previous studies in
canine or human circulation (29–33). These differences may
be partly due to the longer duration of NAC administration
(27,31) or its intravenous, as opposed to intraarterial,
delivery (31,33) in previous studies that may have altered the
bioavailability of NAC. Finally, Creager and associates (27)
studied normal subjects, whereas the majority of our pa-
tients had atherosclerosis or its risk factors.
Sodium nitroprusside releases NO by an endothelium-
independent mechanism in the presence reducing agents
such as thiols that are present in plasma and tissue extracts
(34,35). A previous human study demonstrated no poten-
tiation of systemic or pulmonary hemodynamic effects of
SNP with NAC (36), a finding that is in agreement with
our results in the femoral microcirculation. Our study,
however, demonstrates that NAC augments SNP-mediated
coronary epicardial and microvascular dilation, suggesting
that thiols, such as cysteine, contribute to more rapid
generation of NO from SNP in the human coronary
circulation.
Study limitations. Because there is no current method to
administer NO directly into the coronary circulation, we
were unable to directly assess the effects of NAC on NO.
Even if this had been achieved, exogenous NO would
instantly form adducts with circulating endogenous thiols.
We also cannot exclude the unlikely possibility that en-
hancement of ACH responses by NAC was independent of
NO, but we recently demonstrated that the improvement
with another thiol, glutathione, is mediated through in-
creased NO bioavailability (19).
Caution should be advised in interpreting the effects of
Figure 5. Change in femoral vascular resistance index (FVRI) with acetylcholine (left panel), sodium nitroprusside (middle panel) and nitroglycerin (right
panel) before (control) and after N-acetylcysteine (NAC). P values with and without NAC are compared by analysis of variance.
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NAC on the coronary epicardial vessels because epicardial
diameter did not return to baseline in some patients after
NTG and NTP were administered. To overcome this, we
analyzed the effects of repeat administration of the agonists
after NAC only in those patients in whom epicardial
diameters returned to baseline. We may have missed im-
provement in the NTG responses because of near maximal
epicardial vasodilation observed at the doses employed.
However, augmentation in SNP responses was detectable
with vasodilation at baseline similar to that of NTG.
Conclusions and implications. In this study, we demon-
strate that coronary endothelium-dependent and SNP-
mediated vasodilation is improved by NAC. This acute
improvement in endothelial function and the recent dem-
onstration that S-nitrosoglutathione has platelet inhibitory
effects in humans indicate that thiols such as NAC and
glutathione may have therapeutic potential (19,37,38). The
combination of NTG and NAC significantly reduced the
incidence of myocardial infarction compared with NTG
alone in patients with severe unstable angina (39). Further-
more, an inhibitory effect of S-nitrosoalbumin on neointi-
mal proliferation and of L-2-oxothiazolidine-4-carboxylic
acid, a cysteine prodrug, on improving endothelial dysfunc-
tion, suggests that long acting NO-adducts may have
antiatherogenic properties (40,41).
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